RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Ke-Da Yu Chen Yang Lei Fan Ao-Xiang Chen Zhi-Ming Shao
- چاپ و سال / کشور: 2010
Description
A single-nucleotide polymorphism (SNP) in the 50-untranslated region (UTR) of RAD51, 135G[C (rs1801320), was reported to be associated with an increased risk of breast cancer among BRCA2 as well as BRCA1 carriers. A few studies have also investigated the genetic contribution of RAD51 135G[C to the risk of sporadic breast cancers or breast cancer in non-BRCA1/2 carriers, though the results are yet controversial and inconclusive. We, in this study, performed a more precise estimation of the relationship between 135G[C and breast cancer among non-BRCA1/2 mutation carriers by meta-analyzing the currently available evidence from the literature.A total of 12 studies involving 7,065 cases and 6,981 controls were identified. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association. When all the studies were pooled into the meta-analysis, there was no evidence for a significant association between 135G[C and breast cancer risk in non-BRCA1/2 mutation carriers (for CC vs. GG: OR = 0.995, 95%CI: 0.741–1.336; for GC vs. GG: OR = 0.959, 95%CI: 0.869– 1.057; for dominant model: OR = 0.988, 95%CI: 0.902– 1.082; and for recessive model: OR = 1.037, 95%CI: 0.782–1.376). We also performed subgroup analysis by ethnicity (Caucasian) as well as did analysis using the studies fulfilling Hardy–Weinberg equilibrium, and the results did not change. In summary, the present meta-analysis suggests that the RAD51 135G[C does not modify breast cancer risk in non-BRCA1/2 mutation carriers.
Breast Cancer Res Treat (2011) 126:365–371 Received: 29 April 2010 / Accepted: 3 May 2010 / Published online: 12 May 2010 Springer Science+Business Media, LLC. 2010
